SEC Form 4 · accession 0001209191-18-055475
PhaseBio Pharmaceuticals Inc · PHAS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan P Mow
Officer — Chief Executive Officer · Director
Period of report
Oct 17, 2018
Accepted (ET)
Oct 17, 2018 · 9:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001169245
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $5.00 | Oct 17, 2018 | A | 220,000 | A | — | Oct 17, 2028 | Common Stock | 220,000 | 220,000 | D |
Explanation of responses
- F1The shares subject to the option shall vest in equal monthly installments over 48 months from October 17, 2018, subject to the reporting person's continued service through each such date.